DRG2

Across TCGA pan-cancer cohorts, DRG2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated DRG2 data layer compared with 27 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher DRG2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated DRG2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and UCEC show a favorable association.

GBM, PDAC, and UCEC are the cancer types where DRG2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	OS	Quartile	All	0.321	0.630	.011	11	view →
PDAC	DFS	Median	III,IV	0.708	0.315	.011	8	view →
UCEC	DFS	Median	All	0.954	0.860	.041	8	view →
COAD	DFS	Median	III,IV	1.000	0.844	.044	6	view →
LSCC	OS	Median	III,IV	0.996	0.687	.023	5	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

DRG2–GBM (OS)

Open the GBM breakdown →